LPX-TI641

N/A

Report date: 2023/09/25 10:41:19
NME

Base Information

Drug NameLPX-TI641
Drug Alias NameLPX-TI-641
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatitis A virus cellular receptor 2 agonistsT-cell immunoglobulin and mucin domain-containing protein 4 agonists
TargetsHepatitis A virus cellular receptor 2T-cell immunoglobulin and mucin domain-containing protein 4
Therapy Area/IndicationsAutoimmune DiseasesPsoriasisDermatitis, Atopic +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesJordan
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesLAPIX Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesLAPIX Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesPsoriasisDermatitis, Atopic +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A